Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 12, 2021
Reporting Period: Event date April 12, 2021
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate governance event regarding a material agreement.
Material Changes
Termination of Material Definitive Agreement: The Company terminated a purchase agreement originally entered into on May 15, 2019, with Lincoln Park Capital Fund, LLC ("Lincoln Park"). The termination was effected via a letter dated April 12, 2021, in accordance with the terms of the Agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing states the termination was executed as permitted under the Agreement's terms. No forward-looking guidance, outlook, or specific risk factors related to future operations are detailed in this specific report.
Unusual Items: The termination of the 2019 purchase agreement is the primary unusual item reported.
Investor Verification Checklist
- Verify the specific terms of the terminated 2019 purchase agreement with Lincoln Park Capital Fund, LLC to understand potential financial or operational impacts.
- Review the May 16, 2019 Form 8-K to understand the original scope and conditions of the agreement.
- Confirm if the termination triggers any remaining obligations or penalties under the original contract.
- Check subsequent filings for any new financing arrangements replacing the terminated agreement.